key: cord-0747083-1qxrbwoj authors: Osborne, Vicki title: Opioids in the United Kingdom: safety and surveillance during COVID-19 date: 2021-05-14 journal: Curr Opin Psychiatry DOI: 10.1097/yco.0000000000000719 sha: f817e256e3c2e55c552486a0730d86d298dd2a75 doc_id: 747083 cord_uid: 1qxrbwoj PURPOSE OF REVIEW: Opioid use is prevalent in the United Kingdom and prior to the COVID-19 pandemic it had been recognized that the safety of opioids was an important issue to be monitored by the UK medicines regulatory agency. With the emergence of COVID-19, this requirement has been even greater. This review was undertaken to determine the impact of the pandemic on safety and surveillance of opioids in the United Kingdom. RECENT FINDINGS: During the COVID-19 pandemic, the surveillance of opioids in the United Kingdom continued, although primary research was often conducted with data prior to the pandemic. Of those studies that were conducted while the pandemic was ongoing, access to opioids (or opioid substitution therapy) and the subsequent effect on patient safety was the main theme. SUMMARY: In the United Kingdom, changes in accessibility to the healthcare system and how healthcare providers operated during the COVID-19 pandemic may have had unintended consequences on use and safety of opioids, due to the shift in focus to preventing COVID-19 from overwhelming the healthcare system. The findings from this review support the need to continue surveillance in the United Kingdom, including the impact of the COVID-19 pandemic on opioid utilization and safety. The opioid crisis in the United States is ongoing and well publicized, with overdoses involving opioids contributing to over two-thirds (67.8%) of overdose deaths in the United States in 2017 alone (47 600 deaths in total) [1, 2] . The United Kingdom has not seen the same levels of use as in the United States, though this does not mean safety of opioids is not an issue or should not be monitored. In 2017/2018, 12.8% of the adult population in England were prescribed opioids [3] . While this is a decrease in prescriptions from 2016, opioid use in general requires ongoing surveillance to ensure frequency of adverse events is not greater than anticipated and does not result in a negative risk-benefit profile [3] . This figure from the National Health Service (NHS) Business Services Authority also only accounts for prescribed opioids and does not consider use of opioids obtained without a prescription or illicit opioids such as heroin. In England, 1829 opioidrelated deaths (including illicit opioids) were reported in 2017, with 815 opioid-related deaths reported in Scotland the same year [4] . This represented a doubling on 2007 figures in Scotland and a 40% increase from 2007 in England [4] . Scotland has the highest drug-related death rate in Europe (17 per 100 000 in 2017) [5] and opioid deaths have increased further since 2017 (1021 deaths in 2018 [6] and 1092 deaths in 2019 [7] ). In addition, codeine use increased five-fold between 2006 and 2017 in the United Kingdom, to 2456 prescriptions per 10 000 persons/year. Other opioid prescribing rates also increased during this period and following initiation, 14.6% of patients progressed to long-term use (defined as at least three opioid prescriptions issued within a 90-day period, or 1 opioid prescription lasting at least 90 days) in the first year [8] . It is acknowledged that this is a high proportion progressing to long-term use, though definitions of long-term use vary and other studies have focused on diagnostic outcomes such as opioid dependence instead [9] . The UK Medicines and Healthcare Regulatory Agency (MHRA) has recognized the importance of assessing the benefits and risks of opioid medications, with the launch of an Opioid Expert Working Group [10] . This group has already recommended that the labelling for opioid medicines must carry a warning that informs patients about the risk of addiction, which was accepted by the MHRA in April 2019 [11] . The MHRA also announced in September 2020 that additional, strengthened warnings were to be added to the patient information leaflets of all opioids about the risk of dependence and addiction [12] . Opioid surveillance varies among countries; the majority of countries have systems in place to monitor prescription and over the counter opioids, as with all licensed medications. Monitoring often examines prescriptions issued, adverse drug reactions and deaths due to overdose. Spontaneous reporting is the most frequently used method for monitoring adverse drug reactions, which relies on physician and patient reporting and is known to be subject to under-reporting [13] . In the United Kingdom, the yellow card system is used for capturing spontaneous reports, while in Europe these are reported to EudraVigilance [14, 15] . Illicit opioid use is monitored primarily through surveys, such as the Crime Survey for England and Wales or the National Survey on Drug Use and Health in the United States [16, 17] ; however, routine surveillance may not be in place in all countries. Despite encouraging steps in recognizing the importance of opioid surveillance in the United Kingdom, the arrival COVID-19 in 2020 may have impacted monitoring plans. For several months, the NHS cancelled nonurgent services in an attempt to avoid overwhelming the health service, due to the rapid increase in COVID-19 cases. While a return to some services occurred later in the year, it is unclear how those using opioids (illicit or prescribed) were affected. In addition, with such an intense focus on COVID-19, there remains a risk that opioid surveillance has been put to one side during the pandemic. Consequently, the aim of this review was to determine the impact of the COVID-19 pandemic on safety and surveillance of opioids in the United Kingdom. A literature search was conducted in PubMed using the following search strategy: [(Opioid) AND (UK OR United Kingdom OR England OR Scotland OR Wales OR Northern Ireland)] AND (Safety OR surveillance OR monitoring) The search was restricted to publications between 1 August 2019 and 1 January 2021. In total, 307 articles were identified from this search. After screening titles and abstracts, 24 articles were reviewed for potential inclusion in the review, with a final focus on 10 original research articles as references of special interest. Other online resources were also used as references where appropriate. The review identified relatively few research studies that were conducted during the COVID-19 pandemic; several studies were conducted and published prior to the pandemic. One such study examined drugs associated with intentional overdose and found that risk of death was 12 times higher for opioids compared with nonopioid analgesics [18] . This study was conducted in the Republic of Ireland, rather than the United Kingdom, but provides useful statistics which inform on opioid safety in general. Another study examined the epidemiology of opioid use in the United Kingdom and the association with mortality [19] , informing on opioid utilization and safety. A further study examined the benefit-risk profile of the buprenorphine implant for treatment of opioid dependence, conducted as part of the licensing application in Europe [20] . A favourable benefit-risk profile was observed [20] and the buprenorphine implant was approved for use in Europe in 2019 [21] . Other studies identified in the review were conducted prior to the pandemic and published during the pandemic time period. Several of these articles were not focussed primarily on opioids, but recognized the high prevalence of co-use with other drugs (e.g. gabapentinoids) and the importance of monitoring co-use [22] . Surveillance of treatment for substance use disorders (including opioid use disorder) and coprescription of other drugs was also examined [23] , as were long-term outcomes for mothers of infants with neonatal abstinence syndrome [24] . Surveillance of opioids and their safety continued in the United Kingdom during the COVID-19 pandemic. Changes in health care during the COVID-19 pandemic may have had unintended consequences on use and safety of opioids. Further articles were not specifically focused on surveillance in the United Kingdom but included UK data; for example, Layne et al. [25] examined nonmedical use of tramadol in several European countries. Several opinion pieces and reviews were published during the COVID-19 time frame and specifically focused on the potential impact of the pandemic on opioid prescribing, safety and surveillance. While these articles do not contribute original research data, they provide useful insights in to the desire to continue opioid research during COVID-19. Some articles focused on opioids, substance use disorder and patient care during the COVID-19 pandemic [26] [27] [28] , recognizing that services could be impacted by pressure on, or changes in, the healthcare system [29, 30] . Since opioids are often used in end-of-life and palliative care, ensuring continued availability and effective use is vital given known morbidity and mortality with COVID-19. Further to these articles, 10 original research articles of special interest were selected for further detailed discussion in this review. An article published in February 2020 by Scott et al. [31 & ] evaluated a primary care-based opioid and pain review service using a mixed methods approach. In the United Kingdom, primary care refers to the management of patients with a general practice setting, which is where the majority of patients are managed unless they require specialist treatment. This study was conducted in two general practice practices in England between 2016 and 2017. In total, 34 patients enrolled in the novel service and a decrease in median prescribed opioid dose was observed from baseline (P < 0.0001). Improvements in health, wellbeing and quality of life were also observed [31 & ]. The authors concluded that the service was well received overall and appeared to have potential benefits, warranting further exploration of this care pathway through a randomized controlled trial. A further article published in February 2020 by Kesten et al. [32 & ] provided further results from the same general practice practices for 2017-2018. The findings from this article supported the conclusions from 2016 to 2017 [32 & ]. Appropriate pain management and support of patients prescribed opioids is critical to ensure effective treatment. The development of novel services within primary care, where most UK patients will be managed, is not only an important advancement but could potentially improve patient outcomes. A mixed methods analysis was conducted by Gibson et al. [33 && ] to examine safety incidents with methadone or buprenorphine as opioid substitution therapy in England and Wales, published in March 2020. The study itself was conducted between 2005 and 2015 and concluded that most risks from opioid substitution treatments arose from failures in care delivery processes [33 && ]. Specifically, these failures included insufficient or lack of patient supervision during dispensing, insufficient monitoring or communication with patients, and incomplete or inaccurate prescribing. Failures were reported to have occurred due to both attentional slips by staff members and poor working conditions (including overloading staff) [33 && ]. This evidence highlights the importance of well managed care to ensure patient safety during opioid substitution treatment, emphasizing that patient outcomes are not only dependent on the treatment prescribed but also the supportive care provided. A further article by Jones et al. ]. It was noted that both error and bias could affect results; however, the ability to conduct such linkage is important for studying associations between treatment and substance-related harm. Overall, the use of these novel methods for monitoring substance use disorder and patient outcomes can help identify the magnitude of these conditions in the United Kingdom. In addition, using pre-existing data is often more cost-effective than other surveillance methods. In England, codeine containing products can be sold without a prescription in pharmacies (over the counter), though it is a requirement to consult with a pharmacist before purchase. In a qualitative study ]. For those who also used heroin, reduced local heroin availability influenced tampering with codeine containing medicines to avoid opioid withdrawal. Restrictions on codeine sourcing in pharmacies also played an influential role [36 & ]. Overall, the study results support the assertion that such tampering should be considered in risk assessments for opioids. A study by Zhao et al. [37 & ] published in July 2020, examined designing effective warnings about addiction for the patient information leaflet provided with the packaging for nonprescription codeine products. Their efforts were specifically focused on targeting these warnings to university students and they gained feedback from participants. The study identified that 47% of 30 participating students felt there should be tight restrictions on regulation due to the addiction potential of codeine [37 & ]. Useful feedback on the design of these information leaflets was also obtained. Nonprescription codeine safety was also explored by Mody et al. ]. Specific to the COVID-19 pandemic, the authors noted that customer numbers in pharmacies may have been reduced during the study period and that pharmacies were selected taking into account the operational impact of COVID-19. Of 3993 interactions recorded, 5.5% of customers who were known to staff and frequently bought codeine products chose not to purchase any pain relief products, compared with 1.1% of unknown customers (P < 0.0001) [38 && ]. The card was found to be easy to use by staff and the majority of patients accepted the card when offered. The results of the study suggest that community pharmacists can be involved in behavioural change regarding purchasing codeine, which could assist in decreasing misuse [38 && ]. These studies highlight the potential risks of codeine containing products which are available to purchase without a prescription. They also highlight risk mitigation measures which could have valuable impact, such as new or revised educational materials and further educational intervention by pharmacists. Opioids are frequently prescribed in the United Kingdom as part of palliative and end-of-life care, to relieve pain and suffering. Research into the effect of the COVID-19 pandemic on these services is important to understand any changes in opioid use during this period, which could in turn influence patient comfort or safety. Antunes et al. [39 && ] conducted a survey in the United Kingdom and Ireland in April 2020 to investigate clinician experiences of changes in anticipatory prescribing during the COVID-19 pandemic and their recommendations for changes in process. Anticipatory prescribing occurs in advance of clinical need for symptom management at the end of life. April 2020 was a challenging period in the United Kingdom for health care, when the country was under lockdown and many nonessential health services had been suspended due to a surge in COVID-19 cases. There was a concern that the NHS would become overwhelmed unless COVID-19 cases decreased. Of 261 replies to the survey, 47% reported changes in route of administration during the pandemic [39 && ]. For example, it was noted that oral/buccal routes provide more control to the patient without the need for a healthcare professional (to administer injections) [39 && ]. Other findings included changes in the drugs prescribed (38%), with one participant noting an increase in off-label use, in addition to changes in the quantities of drugs prescribed (35%) [39 && ]. A specific comment was made that smaller quantities were being prescribed to preserve stocks [39 && ]. Overall, the results from this survey highlight changes in prescribing behaviour for opioids in the United Kingdom during the COVID-19 pandemic which may in turn have influenced both patient care and safety. The authors concluded that the effectiveness of such approaches needs to be researched, in addition to whether they would persist beyond the pandemic [ ]. Both of these studies indicate that demand for opioids not only persisted but may have increased during the COVID-19 pandemic, due to use in end-of-life care. These findings further support the need for ongoing surveillance, to ensure both adequate supply and appropriate patient care. During the COVID-19 pandemic, the surveillance of opioids in the United Kingdom continued, although primary research was often conducted with data prior to the pandemic. Of those studies that were conducted while the pandemic was ongoing, access to opioids (or opioid substitution therapy) and the subsequent effect on patient safety was the main theme. In the United Kingdom, changes in accessibility to the healthcare system and how healthcare providers operated during the COVID-19 pandemic may have had unintended consequences on use and safety of opioids, due to the shift in focus to preventing COVID-19 from overwhelming the healthcare system. The findings from this review support the need to continue surveillance in the United Kingdom, including the impact of the COVID-19 pandemic on opioid utilization and safety. Drug and opioid-involved overdose deaths -United States Drug overdose deaths Prescribed medicines review: report. Public Health England Rising opioid-related deaths in England and Scotland must be recognised as a public health crisis The UK Government must help end Scotland's drug-related death crisis Drug-related deaths in Scotland Drug-related deaths in Scotland in 2019: national records of Scotland Time trends and prescribing patterns of opioid drugs in UK primary care patients with noncancer pain: a retrospective cohort study Pharmaceutical opioid use and dependence among people living with chronic pain: associations observed within the pain and opioids in treatment (POINT) cohort Opioid Expert Working Group meets at MHRA All opioid medicines in UK to carry prominent warnings MHRA. UK regulator strengthens opioid warnings. Medicines and Healthcare Regulatory Agency Under-reporting of adverse drug reactions: a systematic review National Survey on Drug Use and Health (NSDUH): Substance Abuse and Mental Health Services Administration (SAMHSA). 2021; Avail A national case fatality study of drugs taken in intentional overdose The epidemiology of regular opioid use and its association with mortality: prospective cohort study of 466 486 UK biobank participants Systematic benefit-risk assessment for buprenorphine implant: a semiquantitative method to support risk management European Medicines Agency Trends in gabapentinoid prescribing, co-prescribing of opioids and benzodiazepines, and associated deaths in Scotland Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records Long-term mortality in mothers of infants with neonatal abstinence syndrome: a population-based parallelcohort study in England and Ontario, Canada Acute toxicity related to misuse (nonmedical use) of tramadol: experience of the European Drug Emergencies Network Plus COVID-19 and the health of people who use drugs: what is and what could be? COVID-19 and substance use disorders: recommendations to a comprehensive healthcare response. An International Society of Addiction Medicine Practice and Policy Interest Group Position Paper COVID-19, HIV and key populations: crosscutting issues and the need for population-specific responses Transmucosal drug administration as an alternative route in palliative and end-of-life care during the COVID-19 pandemic Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic Evaluation of a primary care-based opioid and pain review service: a mixed-methods evaluation in two GP practices in England Conducted among 34 patients enrolled in a novel service provided at two general practice practices in England between Acceptability of a primary care-based opioid and pain review service: a mixed-methods evaluation in England Conducted among 34 patients enrolled in a novel service provided at two general practice practices in England between A mixed-methods analysis of patient safety incidents involving opioid substitution treatment with methadone or buprenorphine in community-based care in England and Wales Conducted using 2284 reports of safety incidents involving opioid substitution treatment submitted between Designing effective warnings about addiction on the patient information leaflet of over-the-counter codeine sold in England to university students Anticipatory prescribing in community end-of-life care in the UK and Ireland during the COVID-19 pandemic: online survey An audit of end-of-life symptom control in patients with corona virus disease 2019 (COVID-19) dying in a hospital in the United Kingdom Patients dying of COVID-19 experienced similar end-of-life problems to other groups of patients and generally responded to standard interventions for these end-of-life problems Financial support and sponsorship None.